# US 2008/0306048 A1 · Therapeutic pyrazoloquinoline urea derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306048 A1
- Document ID: US20080306048A1
- Status: Published application
- Kind: A1
- Application number: 12/135,023
- Filed: 2008-06-06
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Assignees: Helicon Therapeutics, Inc.
- Inventors: Alan P. Kaplan; Varsha Gupta
- Web page: https://patentgrep.com/patent/US20080306048A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and modulating GABAA, and use of the compound of formula I for the treatment of GABAA receptor associated disorders. The general structure of formula I is shown below: The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, hydroxy, halo, cyano, —CONRaRb, —NRaRb, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocycle, amino(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
each Ra and Rb are independently hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkylOC(O)—, or arylOC(O)—, or Ra and Rb are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Rd; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S(O)z, and NRc;
each z is an integer selected from 0, 1, and 2;
each R1 is independently hydrogen, (C2-C6)alkenyl, (C2-C6)alkynyl, —C(O)O(C1-C6)alkyl, —C(O)Oaryl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkylO(CH2)m—, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocycle, arylO(C1-C6)alkyl, —C(O)NRg(C1-C6)alkyl, —C(O)NRgaryl, —S(O)z(C1-C6)alkyl, —S(O)zaryl, —C(O)(C1-C6)alkyl, arylC(O)—, (C1-C6)alkyl optionally substituted with up to 5 fluoro, or (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
each m is an integer selected from 2, 3, 4, 5, and 6;
each Rd is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, —C(O)NRaRb, —NRaRb, hydroxy(C1-C6)alkyl, aryl, aryl(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
Re and Rf are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, —S(O)z(C1-C6)alkyl, —S(O)zaryl, —CONRg(C1-C6 alkyl), (C1-C6)alkylC(O)—, arylC(O)—, (C1-C6)alkylOC(O)—, and arylOC(O)—;
Rg is hydrogen or (C1-C6)alkyl;
R5 and R6 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, and aryl, or R5 and R6 are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Rd; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S(O)z, and NRc;
R7 is selected from the group consisting of hydrogen, hydroxy, halo, hydroxy(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
Ar is aryl, or heteroaryl, each optionally substituted with one or more R8; and
each R8 is independently hydrogen, halo, CF3, CF2H, hydroxy, cyano, nitro, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, —NRaRb, aryl, heteroaryl or heterocycle.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Ar is a heteroaryl selected from the group consisting of thienyl and pyridyl, each optionally substituted with one or more R8.

### Claim 3 (depends on 1)

The compound of claim 1,
wherein:
R1, R2, R3, and R4 are each independently hydrogen, halo, cyano, (C1-C6)alkyl optionally substituted with up to 5 fluoro, or (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
R5 and R6 are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Rd; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), and NRc; and
R7 is hydrogen or (C1-C6)alkyl optionally substituted with up to 5 fluoro.

### Claim 4 (depends on 1)

The compound of claim 1 that has the formula Ia:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R5 and R6, together with the nitrogen to which they are attached, form a piperidinyl, pyrrolidinyl, morpholinyl, or thiomorpholinyl ring.

### Claim 6 (depends on 1)

The compound of claim 1 that has the formula Ib
or a pharmaceutically acceptable salt thereof,
wherein:
X is N(Rc), O (oxygen), C(Rd)2, or S(O)z;
z is an integer selected from 0, 1, and 2;
each Rd is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, —C(O)NRaRb, —NRaRb, hydroxy(C1-C6)alkyl, aryl, aryl(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro; and
n is an integer selected from 0, 1, and 2; with the proviso that when n=0 then X is C(Rd)2.

### Claim 7 (depends on 6)

The compound of claim 6 that has the formula Ic:
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 4)

The compound of claim 4 that has the formula Id:
or a pharmaceutically acceptable salt thereof,
wherein
n is an integer selected from 0, 1, and 2.

### Claim 9 (depends on 8)

The compound of claim 8 wherein n is 0.

### Claim 10 (depends on 8)

The compound of claim 8 wherein n is 1.

### Claim 11 (depends on 8)

The compound of claim 8 wherein n is 2.

### Claim 12 (depends on 8)

The compound of claim 8 wherein R2 is Methyl.

### Claim 13 (depends on 8)

The compound of claim 8 wherein R2 is trifluoromethyl.

### Claim 14 (depends on 8)

The compound of claim 8 wherein R2 is fluoro.

### Claim 15 (depends on 8)

The compound of claim 8 wherein R2 is OMe.

### Claim 16 (depends on 8)

The compound of claim 8 wherein R3 is Methyl.

### Claim 17 (depends on 8)

The compound of claim 8 wherein R3 is fluoro.

### Claim 18 (depends on 8)

The compound of claim 8 wherein R3 is OMe.

### Claim 19 (depends on 8)

The compound of claim 8 wherein R7 is Methyl.

### Claim 20 (depends on 8)

The compound of claim 8 wherein R2 and R3 are fluoro.

### Claim 21 (depends on 8)

The compound of claim 8 wherein R2 and R3 are Methyl.

### Claim 22 (depends on 8)

The compound of claim 8 wherein R2 is fluoro and R3 is methyl.

### Claim 23 (depends on 8)

The compound of claim 8 that has the formula Ie:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The compound of claim 1 that has the formula II:
or a pharmaceutically acceptable salt thereof,
wherein:
each Y is independently N or C(R8).

### Claim 25 (depends on 24)

The compound of claim 24 wherein R5 and R6, together with the nitrogen to which they are attached, form a piperidinyl, pyrrolidinyl, morpholinyl, or thiomorpholinyl ring, each optionally substituted with one or more Rd.

### Claim 26 (depends on 24)

The compound of claim 24 that has the formula IIb:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The compound of claim 26 wherein n is 0.

### Claim 28 (depends on 26)

The compound of claim 26 wherein n is 1.

### Claim 29 (depends on 26)

The compound of claim 26 wherein n is 2.

### Claim 30 (depends on 26)

The compound of claim 26 wherein R2 is Methyl.

### Claim 31 (depends on 26)

The compound of claim 26 wherein R2 is trifluoromethyl.

### Claim 32 (depends on 26)

The compound of claim 26 wherein R2 is fluoro.

### Claim 33 (depends on 26)

The compound of claim 26 wherein R2 is OMe.

### Claim 34 (depends on 26)

The compound of claim 26 wherein R3 is Methyl.

### Claim 35 (depends on 26)

The compound of claim 26 wherein R3 is fluoro.

### Claim 36 (depends on 26)

The compound of claim 26 wherein R3 is OMe.

### Claim 37 (depends on 26)

The compound of claim 26 wherein R7 is Methyl.

### Claim 38 (depends on 26)

The compound of claim 26 wherein R2 and R3 are fluoro.

### Claim 39 (depends on 26)

The compound of claim 26 wherein R2 and R3 are Methyl.

### Claim 40 (depends on 26)

The compound of claim 26 wherein R2 is fluoro and R3 is methyl.

### Claim 41 (depends on 26)

The compound of claim 26 that has the formula IIc:
or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The compound of claim 41 that has the formula IId:
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 41)

The compound of claim 41 that has the formula IIe:
or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 41)

The compound of claim 41 that has the formula IIf:
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1)

The compound of claim 1 that is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 1)

A pharmaceutical composition comprising:
a) a compound of claim 1; and
b) a pharmaceutically acceptable carrier.

### Claim 47

A method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, hydroxy, halo, cyano, —CONRaRb, —NRaRb, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocycle, amino(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
each Ra and Rb are independently hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkylOC(O)—, or arylOC(O)—, or Ra and Rb are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Rd; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S(O)z, and NRc;
each z is an integer selected from 0, 1, and 2;
each R1 is independently hydrogen, (C2-C6)alkenyl, (C2-C6)alkynyl, —C(O)O(C1-C6)alkyl, —C(O)Oaryl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkylO(CH2)m—, hydroxy(C1-C6)alkyl, aryl, heteroaryl, heterocycle, arylO(C1-C6)alkyl, —C(O)NRg(C1-C6)alkyl, —C(O)NRgaryl, —S(O)z(C1-C6)alkyl, —S(O)zaryl, —C(O)(C1-C6)alkyl, arylC(O)—, (C1-C6)alkyl optionally substituted with up to 5 fluoro, or (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
each m is an integer selected from 2, 3, 4, 5, and 6;
each Rd is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, —C(O)NRaRb, —NRaRb, hydroxy(C1-C6)alkyl, aryl, aryl(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
Re and Rf are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, —S(O)z(C1-C6)alkyl, —S(O)zaryl, —CONRg(C1-C6 alkyl), (C1-C6)alkylC(O)—, arylC(O)—, (C1-C6)alkylOC(O)—, and arylOC(O)—;
Rg is hydrogen or (C1-C6)alkyl;
R5 and R6 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, and aryl, or R5 and R6 are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Rd; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S(O)z, and NRc;
R7 is selected from the group consisting of hydrogen, hydroxy, halo, hydroxy(C1-C6)alkyl, (C1-C6)alkyl optionally substituted with up to 5 fluoro, and (C1-C6)alkoxy optionally substituted with up to 5 fluoro;
Ar is aryl, or heteroaryl, each optionally substituted with one or more R8; and
each R8 is independently hydrogen, halo, CF3, CF2H, hydroxy, cyano, nitro, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, —NRaRb, aryl, heteroaryl or heterocycle.

### Claim 48 (depends on 47)

The method of claim 47 wherein the modulation is negative.

### Claim 49 (depends on 47)

The method of claim 47 wherein the modulation is positive.

### Claim 50 (depends on 47)

The method of claim 47 wherein the GABAA subtypes is GABAA α5.

### Claim 51 (depends on 50)

The method of claim 50 wherein the modulation is negative.

### Claim 52 (depends on 50)

The method of claim 50 wherein the modulation is positive.

### Claim 53 (depends on 47)

The method of claim 47 further comprising treatment of cognitive dysfunction in an animal.

### Claim 54 (depends on 48)

The method of claim 48 further comprising treatment of cognitive dysfunction in an animal.

### Claim 55 (depends on 50)

The method of claim 50 further comprising treatment of cognitive dysfunction in an animal.

### Claim 56 (depends on 1)

A method of increasing cognitive function in an animal comprising administering to the animal an effective amount of the compound of claim 1, under conditions wherein memory is increased.

### Claim 57 (depends on 56)

The method of claim 56 wherein the animal is healthy.

### Claim 58 (depends on 56)

The method of claim 56 wherein the memory is long term memory.

### Claim 59 (depends on 56)

The method of claim 56 wherein the memory is short term memory.

### Claim 60 (depends on 1, 46)

A method of treatment of cognitive dysfunction in an animal comprising administering to the animal an effective amount of the compound of claim 1 or the composition of claim 46, under conditions wherein the cognitive dysfunction is treated.

### Claim 61 (depends on 60)

The method of claim 60 wherein one or more GABAA subtypes in the animal are negatively modulated.

### Claim 62 (depends on 61)

The method of claim 61, wherein the GABAA subtypes is GABAA α5.

### Claim 63 (depends on 60)

The method of claim 60, wherein the animal is a mammal.

### Claim 64 (depends on 60)

The method of claim 60, wherein the animal is an aged animal.

### Claim 65 (depends on 60)

The method of claim 60, wherein the cognitive dysfunction is Alzheimer's disease, dementia or another neurodegenerative disease.
